Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Erbitux’s marginal clinical benefit in lung cancer could prompt second look from regulators
Erbitux’s marginal clinical benefit in lung cancer could prompt second look from regulators
Erbitux’s marginal clinical benefit in lung cancer could prompt second look from regulators
Submitted by
admin
on August 13, 2009 - 9:05pm
Source:
FT.com
News Tags:
cancer
Eli Lilly
Erbitux
Headline:
Erbitux’s marginal clinical benefit in lung cancer could prompt second look from regulators
Do Not Allow Advertisers to Use My Personal information
